<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32762033</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle><sup>11</sup> C-PK11195 PET-based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1513</StartPage><EndPage>1523</EndPage><MedlinePgn>1513-1523</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51112</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Neuroinflammation is considered a key driver for neurodegeneration in several neurological diseases, including amyotrophic lateral sclerosis (ALS). SOD1 mutations cause about 20% of familial ALS, and related pathology might generate microglial activation triggering neurodegeneration. <sup>11</sup> C-PK11195 is the prototypical and most validated PET radiotracer, targeting the 18-kDa translocator protein which is overexpressed in activated microglia. In this study, we investigated microglia activation in asymptomatic (ASYM) and symptomatic (SYM) SOD1 mutated carriers, by using <sup>11</sup> C-PK11195 and PET imaging.</AbstractText><AbstractText Label="METHODS">We included 20 subjects: 4 ASYM-carriers, neurologically normal, 6 SYM-carriers with probable ALS, and 10 healthy controls. A receptor parametric mapping procedure estimated <sup>11</sup> C-PK11195 binding potentials and voxel-wise statistical comparisons were performed at group and single-subject levels.</AbstractText><AbstractText Label="RESULTS">Both the SYM- and ASYM-carriers showed significant microglia activation in cortical and subcortical structures, with variable patterns at individual level. Clusters of activation were present in occipital and temporal regions, cerebellum, thalamus, and medulla oblongata. Notably, SYM-carriers showed microglia activation also in supplementary and primary motor cortices and in the somatosensory regions.</AbstractText><AbstractText Label="INTERPRETATION">In vivo neuroinflammation occurred in all SOD1 mutated cases since the presymptomatic stages, as shown by a significant cortical and subcortical microglia activation. The involvement of sensorimotor cortex became evident at the symptomatic disease stage. Although our data indicate the role of in vivo PET imaging for assessing resident microglia in the investigation of SOD1-ALS pathophysiology, further studies are needed to clarify the temporal and spatial dynamics of microglia activation and its relationship with neurodegeneration.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tondo</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-0057-3103</Identifier><AffiliationInfo><Affiliation>School of Psychology, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0053-9519</Identifier><AffiliationInfo><Affiliation>School of Psychology, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerami</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scuola Universitaria di Studi Superiori IUSS Pavia, Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Mondino Foundation, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanoli</LastName><ForeName>Giovanna Emilia</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Unit, IRCCS and San Raffaele Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Presotto</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Psychology, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masiello</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Unit, IRCCS and San Raffaele Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coliva</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Unit, IRCCS and San Raffaele Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvi</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Bellaria Hospital, IRCCS of Neurological Sciences, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartolomei</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Bellaria Hospital, IRCCS of Neurological Sciences, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosca</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical Genetics Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NeuroMuscular Omnicentre, Serena Onlus Foundation, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perani</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Psychology, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuclear Medicine Unit, IRCCS and San Raffaele Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C504060">(R)-(11C)1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="Y">Amides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007546" MajorTopicYN="Y">Isoquinolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest relevant for this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32762033</ArticleId><ArticleId IdType="pmc">PMC7480909</ArticleId><ArticleId IdType="doi">10.1002/acn3.51112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Robberecht W., Philips T.. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 2013;14:248&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke T., Pinto&#x2010;Grau M., Lonergan K., et al. A cross&#x2010;sectional population&#x2010;based investigation into behavioral change in amyotrophic lateral sclerosis: Subphenotypes, staging, cognitive predictors, and survival. Ann Clin Transl Neurol 2017;4:305&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5420811</ArticleId><ArticleId IdType="pubmed">28491898</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F., Sarnelli M.F., Solara V., et al. Depression and risk of cognitive dysfunctions in amyotrophic lateral sclerosis. Acta Neurol Scand 2019;139:438&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">30712314</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Mazzini L., Mora G.. Disease&#x2010;modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 2020;107986.</Citation><ArticleIdList><ArticleId IdType="pubmed">32062193</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott E.O., Malek A.M., Lacomis D.. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol 2016;138:225&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W.. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 2014;10:661.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M., Al&#x2010;Chalabi A.. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M., Brown R.H.. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 2017;a024125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Chi&#xf2; A., Traynor B.J.. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R., Chi&#xf2; A., Traynor B.J.. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 2018;17:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Sayana P., Zhang X., Le W.. Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener 2013;8:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766231</ArticleId><ArticleId IdType="pubmed">23941283</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.. Novel Aspects on Motor Neuron Disease: The Recent Genetic Studies on ALS. In: Novel Aspects on Motor Neuron Disease. IntechOpen; 2019.</Citation></Reference><Reference><Citation>Turner M.R., Al&#x2010;Chalabi A., Chio A., et al. Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry 2017;88:1042&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J., Quick A., Kolb S.J.. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med 2017;19:267&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">27537704</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Moglia C., Canosa A., et al. ALS phenotype is influenced by age, sex, and genetics: a population&#x2010;based study. Neurology 2020;94:e802&#x2013;e810.</Citation><ArticleIdList><ArticleId IdType="pubmed">31907290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Mazzini L., D&#x2019;Alfonso S., et al. The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology 2018;91:e635&#x2013;e642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O., Powell J.F., Andersen P.M., Al&#x2010;Chalabi A.. ALSoD: A user&#x2010;friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat 2012;33:1345&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansarasa O., Bordoni M., Diamanti L., et al. SOD1 in amyotrophic lateral sclerosis:&#x201c;ambivalent&#x201d; behavior connected to the disease. Int J Mol Sci 2018;19:1345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983710</ArticleId><ArticleId IdType="pubmed">29751510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., McKenna&#x2010;Yasek D., Sapp P.E., et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateal sclerosis. Ann Neurol 1997;41:210&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna K.P., McLaughlin R.L., Byrne S., et al. Delineating the genetic heterogeneity of ALS using targeted high&#x2010;throughput sequencing. J Med Genet 2013;50:776&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812897</ArticleId><ArticleId IdType="pubmed">23881933</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Calvo A., Mazzini L., et al. Extensive genetics of ALS: a population&#x2010;based study in Italy. Neurology 2012;79:1983&#x2013;1989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484987</ArticleId><ArticleId IdType="pubmed">23100398</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S., Ando Y.. Genotype&#x2010;phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl Neurodegener 2015;4:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513711</ArticleId><ArticleId IdType="pubmed">26213621</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowicka N., Juranek J., Juranek J.K., Wojtkiewicz J.. Risk factors and emerging therapies in amyotrophic lateral sclerosis. Int J Mol Sci 2019;20:2616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6600314</ArticleId><ArticleId IdType="pubmed">31141951</ArticleId></ArticleIdList></Reference><Reference><Citation>McCord J.M., Fridovich I.. Superoxide dismutase an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969;244:6049&#x2013;6055.</Citation><ArticleIdList><ArticleId IdType="pubmed">5389100</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S.J., McKeown S.R., Rashid S.. Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis. Gene 2016;577:109&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">26657039</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P., Brown R.H.. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006;7:710&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Schain M., Kreisl W.C.. Neuroinflammation in Neurodegenerative Disorders&#x2014;a Review. Curr Neurol Neurosci Rep 2017;17 10.1007/s11910-017-0733-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-017-0733-2</ArticleId><ArticleId IdType="pubmed">28283959</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Wang F.. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol 2017;8:1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D.. Glial cells in amyotrophic lateral sclerosis. Exp Neurol. 2014;262:111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4241182</ArticleId><ArticleId IdType="pubmed">24859452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S.H., Li Y., Fukaya M., et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci 2013;16:571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Toledo J.B., Van Deerlin V.M., et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One 2012;7:e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Yamanaka K., Lobsiger C.S., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science (80&#x2010; ) 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Werry E.L., Bright F.M., Piguet O., et al. Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders. Int J Mol Sci 2019;20:3161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6650818</ArticleId><ArticleId IdType="pubmed">31261683</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamonti L., Tsvetanov K., Jones P.S., et al. Neuroinflammation and functional connectivity in Alzheimer&#x2019;s disease: interactive influences on cognitive performance. bioRxiv 2019:532291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6733539</ArticleId><ArticleId IdType="pubmed">31320450</ArticleId></ArticleIdList></Reference><Reference><Citation>Surendranathan A., Su L., Mak E., et al. Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain 2018;141:3415&#x2013;3427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6262214</ArticleId><ArticleId IdType="pubmed">30403785</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y., Mozley P.D., Verma A., et al. Noninvasive PK11195&#x2010;PET image analysis techniques can detect abnormal cerebral microglial activation in Parkinson&#x2019;s disease. J Neuroimaging 2018;28:496&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6174975</ArticleId><ArticleId IdType="pubmed">29727504</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Cagnin A., Turkheimer F.E., et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)&#x2010;PK11195 positron emission tomography study. Neurobiol Dis 2004;15:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagnin A., Rossor M., Sampson E.L., et al. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol 2004;56:894&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">15562429</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavese N., Gerhard A., Tai Y.F., et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006;66:1638&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">16769933</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannaccone S., Cerami C., Alessio M., et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson&#x2019;s disease. Parkinsonism Relat Disord 2013;19:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">22841687</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino L., Presotto L., Bettinardi V., et al. An in vivo 11C&#x2010;PK PET study of microglia activation in Fatal Familial Insomnia. Ann Clin Transl Neurol 2018;5:11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5771322</ArticleId><ArticleId IdType="pubmed">29376088</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino L., Moresco R.M., Presotto L., et al. An In Vivo 11 C&#x2010;(R)&#x2010;PK11195 PET and in vitro pathology study of microglia activation in Creutzfeldt&#x2010;Jakob Disease. Mol Neurobiol 2018;55:2856&#x2013;2868.</Citation><ArticleIdList><ArticleId IdType="pubmed">28455699</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo G., Iaccarino L., Caminiti S.P., et al. The combined effects of microglia activation and brain glucose hypometabolism in early&#x2010;onset Alzheimer&#x2019;s disease. Alzheimer's Research &amp; Therapy 2020;12 10.1186/s13195-020-00619-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00619-0</ArticleId><ArticleId IdType="pmc">PMC7193377</ArticleId><ArticleId IdType="pubmed">32354345</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai Y.F., Pavese N., Gerhard A., et al. Microglial activation in presymptomatic Huntington&#x2019;s disease gene carriers. Brain 2007;130:1759&#x2013;1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">17400599</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan&#x2010;Jones W.R., Cope T.E., Jones P.S., et al. In vivo evidence for pre&#x2010;symptomatic neuroinflammation in a MAPT mutation carrier. Ann Clin Transl Neurol. 2019;6:373&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389753</ArticleId><ArticleId IdType="pubmed">30847369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A., Drory V., Hardiman O., et al. A revision of the El Escorial criteria&#x2010;2015. Amyotroph Lateral Scler Front Degener 2015;16:291&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Presotto L., Iaccarino L., Bettinardi V., et al. IEEE nuclear science symposium and medical imaging conference (NSS/MIC). IEEE 2015;2015:1&#x2013;3.</Citation></Reference><Reference><Citation>Matarrese M., Moresco R.M., Cappelli A., et al. Labeling and evaluation of N&#x2010;[11C] methylated quinoline&#x2010;2&#x2010;carboxamides as potential radioligands for visualization of peripheral benzodiazepine receptors. J Med Chem 2001;44:579&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">11170647</ArticleId></ArticleIdList></Reference><Reference><Citation>Turkheimer F.E., Rizzo G., Bloomfield P.S., et al. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans 2015;43:586&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4613512</ArticleId><ArticleId IdType="pubmed">26551697</ArticleId></ArticleIdList></Reference><Reference><Citation>Turkheimer F.E., Edison P., Pavese N., et al. Reference and target region modeling of [11C]&#x2010;(R)&#x2010;PK11195 brain studies. J Nucl Med 2007;48:158&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17204713</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J.. Parametric imaging of ligand&#x2010;receptor binding in PET using a simplified reference region model. NeuroImage 1997;6:279&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">9417971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammertsma A.A., Hume S.P.. Simplified reference tissue model for PET receptor studies. NeuroImage 1996;4:153&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">9345505</ArticleId></ArticleIdList></Reference><Reference><Citation>Comi C., Tondo G.. Insights into the protective role of immunity in neurodegenerative disease. Neural Regen Res 2017;12:64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5319239</ArticleId><ArticleId IdType="pubmed">28250745</ArticleId></ArticleIdList></Reference><Reference><Citation>Sochocka M., Diniz B.S., Leszek J.. Inflammatory response in the CNS: friend or foe? Mol Neurobiol 2017;54:8071&#x2013;8089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684251</ArticleId><ArticleId IdType="pubmed">27889895</ArticleId></ArticleIdList></Reference><Reference><Citation>Motataianu A., Barcutean L., Balasa R.. Neuroimmunity in amyotrophic lateral sclerosis: focus on microglia. Amyotroph Lateral Scler Front Degener 2020;1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31903792</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargiulo S., Anzilotti S., Coda ARD, et al. Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with 18 F&#x2010;DPA&#x2010;714 and micro&#x2010;PET/CT. Eur J Nucl Med Mol Imaging 2016;43:1348&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">26816193</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller A.F., Gravel M., Kriz J.. Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells. Glia 2009;57:1130&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">19115383</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Henkel J.S., Xiao Q., et al. Wild&#x2010;type microglia extend survival in PU. 1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci 2006;103:16021&#x2013;16026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravel M., B&#xe9;land L.&#x2010;C., Soucy G., et al. IL&#x2010;10 controls early microglial phenotypes and disease onset in ALS caused by misfolded superoxide dismutase 1. J Neurosci 2016;36:1031&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601999</ArticleId><ArticleId IdType="pubmed">26791230</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Tauber C., Vercoullie J., et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 2012;7:e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;rcher N.R., Loggia M.L., Lawson R., et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [11C]&#x2010;PBR28. NeuroImage Clin 2015;7:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho M.J., Z&#xfc;rcher N.R., Loggia M.L., et al. Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology 2016;87:2554&#x2013;2561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5207001</ArticleId><ArticleId IdType="pubmed">27837005</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho M.J., Z&#xfc;rcher N.R., Loggia M.L., et al. Integrated magnetic resonance imaging and [11C]&#x2010;PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol 2018;83:1186&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105567</ArticleId><ArticleId IdType="pubmed">29740862</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami C., Iaccarino L., Perani D.. Molecular imaging of neuroinflammation in neurodegenerative dementias: the role of in vivo PET imaging. Int J Mol Sci 2017;18:993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5454906</ArticleId><ArticleId IdType="pubmed">28475165</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Del Tredici K., Toledo J.B., et al. Stages of pTDP&#x2010;43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F., Valsasina P., Riva N., et al. The cortical signature of amyotrophic lateral sclerosis. PLoS One 2012;7:e42816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412820</ArticleId><ArticleId IdType="pubmed">22880116</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E., Veldink J.H., Hendrikse J., et al. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012;83:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">21965521</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhout R., Westeneng H.&#x2010;J., Verstraete E., et al. Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J Neurol Neurosurg Psychiatry 2015;86:288&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">25121571</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RAL, K&#xf6;rner S., Filippini N., et al. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain 2014;137:2546&#x2013;2555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132644</ArticleId><ArticleId IdType="pubmed">24951638</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan R.H., Devenney E., Dobson&#x2010;Stone C., et al. Cerebellar integrity in the amyotrophic lateral sclerosis&#x2010;frontotemporal dementia continuum. PLoS One 2014;9:e105632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140802</ArticleId><ArticleId IdType="pubmed">25144223</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P., Chipika R.H., Finegan E., et al. Brainstem pathology in amyotrophic lateral sclerosis and primary lateral sclerosis: a longitudinal neuroimaging study. NeuroImage Clin 2019;24:102054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6849418</ArticleId><ArticleId IdType="pubmed">31711033</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F., Spinelli E.G., Marjanovic I.V., et al. Unraveling ALS due to SOD1 mutation through the combination of brain and cervical cord MRI. Neurology 2018;90:e707&#x2013;e716.</Citation><ArticleIdList><ArticleId IdType="pubmed">29367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Hammers A., Allsop J., et al. Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8:343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">18033592</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Hammers A., Al&#x2010;Chalabi A., et al. Distinct cerebral lesions in sporadic and &#x2018;D90A&#x2019;SOD1 ALS: studies with [11C] flumazenil PET. Brain 2005;128:1323&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">15843422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A., Valentini M.C., Chi&#xf2; A., et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging 2012;39:251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">22089661</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., Pagani M., Cistaro A., et al. 18F&#x2010;FDG&#x2010;PET correlates of cognitive impairment in ALS. Neurology 2016;86:44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">26590270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala A., Iaccarino L., Fania P., et al. Testing the diagnostic accuracy of [18F] FDG&#x2010;PET in discriminating spinal&#x2010;and bulbar&#x2010;onset amyotrophic lateral sclerosis. Eur J Nucl Med Mol Imaging 2019;46:1117&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">30617963</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A., Pagani M., Montuschi A., et al. The metabolic signature of C9ORF72&#x2010;related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging 2014;41:844&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">24445987</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelnovo V., Caminiti S.P., Riva N., et al. Heterogeneous brain FDG&#x2010;PET metabolic patterns in patients with C9orf72 mutation. Neurol Sci 2019;40:515&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">30554355</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M., Chi&#xf2; A., Valentini M.C., et al. Functional pattern of brain FDG&#x2010;PET in amyotrophic lateral sclerosis. Neurology 2014;83:1067&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K., Vanhee A., Verschueren J., et al. Value of 18fluorodeoxyglucose&#x2013;positron&#x2010;emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol 2014;71:553&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Chun S.J., Boillee S., et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008;11:251&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Visani M., De Biase D., Bartolomei I., et al. A novel T137A SOD1 mutation in an Italian family with two subjects affected by amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011;12:385&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">21574856</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinelli I., Zucchi E., Gessani A., et al. A novel p. N66T mutation in exon 3 of the SOD1 gene: report of two families of ALS patients with early cognitive impairment. Amyotroph Lateral Scler Front Degener 2020;21:296&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">32248719</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg K., Graffmo K., Pakkenberg B., et al. Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD&#x2010;associated genes. J Neurol Neurosurg Psychiatry 2019;90:861&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6691870</ArticleId><ArticleId IdType="pubmed">30992335</ArticleId></ArticleIdList></Reference><Reference><Citation>Gellera C.. Genetics of ALS in Italian families. Amyotroph Lateral Scler Other Mot Neuron Disord 2001;2:s43&#x2013;s46.</Citation><ArticleIdList><ArticleId IdType="pubmed">11465924</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>